Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Merck And Moderna???s Intismeran Plus KEYTRUDA Meets Phase 3 Melanoma Trial Endpoints
2+ hour, 45+ min ago (427+ words) Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene in combination with KEYTRUDA (pembrolizumab) as an adjuvant treatment for patients with completely resected Stage IIB-IV melanoma. The trial met its primary endpoint of recurrence-free…...
moderna-mrna-merck-cancer-melanoma-intismeran-keytruda: Latest Updates
1+ hour, 43+ min ago (46+ words) Audacy Ask your smart speaker to The Chris and Amy Show on KMOX The Dave Glover Show Sports On a Sunday w/ Ackerman Sports on a Sunday Morning The Aul Financial Hour History of the Lou - NewsRadio 1120 KMOX St. Louis…...
Moderna and Merck say mRNA vaccine shows promise for treating melanoma
4+ hour, 43+ min ago (25+ words) NBC 5 Chicago Moderna and Merck say mRNA vaccine shows promise for treating melanoma...
Breakthrough Personalized mRNA Vaccines Are Highly Effective Against Melanoma Skin Cancers
13+ min ago (242+ words) Pharmaceutical companies Moderna and Merck announced today the highly promising results of their anti-cancer mRNA vaccine Phase 3 clinical trial targeting later-stage melanoma skin cancers. Researchers sequenced the DNA from each patient's tumors to create personalized vaccines that, when injected, rev…...
Personalized mRNA-based cancer vaccine shows promise | National/World | centraloregondaily.com
14+ min ago (235+ words) Drugmakers Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large late-stage trial involving high-risk melanoma patients. âââ Subscribe to ABC News on YouTube: https://abcnews.visitlink.me/59aJ1G ABC News is your daily source of breaking…...
'Breakthrough' mRNA cancer drug curbs melanoma in large trial
31+ min ago (425+ words) US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough." The news sent shares in Moderna soaring 145 percent to…...
Moderna, Merck vaccine cuts recurrence and spread of melanoma, raising new treatment hope
46+ min ago (824+ words) A sign marks the headquarters of Moderna in Cambridge, Massachusetts, U.S., April 28, 2022. REUTERS/Brian Snyder By Michael Erman and Julie Steenhuysen Aug 19 (Reuters) - Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and…...
Merck, Moderna Report Positive Results for Their Melanoma Vaccine
1+ hour, 50+ min ago (680+ words) Mexico Business News Join our expert contributor program Merck and Moderna reported the first positive Phase 3 result for an mRNA-based cancer vaccine, intismeran autogene combined with Keytruda, reducing melanoma recurrence in surgically treated patients. Meanwhile, Mexico's COFEPRIS has cut clinical…...
Personalized cancer vaccine shows positive results in “Phase 3”
37+ min ago (247+ words) The experimental personalized cancer vaccine, developed by Moderna and Merck, has yielded positive results in its first Phase 3 trial, bringing the therapy closer to a potential application for regulatory approval. The mRNA technology vaccine, combined with the immunotherapy Keytruda, was…...
Vaccine breakthrough stops cancer returning in trial
49+ min ago (494+ words) A new personalised vaccine given in combination with a drug has stopped skin cancer returning in patients during a trial, representing a potentially watershed moment in cancer treatment. The vaccine, developed by drug companies Merck and Moderna, was given to…...